Diaceutics PLC

Diaceutics PLC

DXRX · LSE · Healthcare / Health Information Services

194.00GBX-1.00 (-0.51%)

Price History

Full chart

Market Stats

Previous Close195.00
Open195.00
Day Range192.50 – 203.00
52-Week Range125.00 – 197.00
Volume320.37K
Market Cap165.54M
P/E (TTM)0.00
Forward P/E40.82
EPS0.00
Dividend Yield0.00%
Beta0.88
50-Day Avg155.16
200-Day Avg153.60

About

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers scientific and advisory services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Ryan Keeling
  • Employees205
  • HeadquartersBuilding Two, Belfast, United Kingdom, BT9 6GW, UK
  • Websitehttps://www.diaceutics.com

Leadership

  • Mr. Peter KeelingFounder & Non-Executive Chairman · b. 1960
  • Mr. Ryan KeelingCEO & Director · b. 1982
  • Mr. Nicholas Stewart RobertsCFO, Secretary & Director · b. 1982
  • Mr. Jordan Russell ClarkChief Data Officer? & Executive Director · b. 1984
  • Kerri DonaldsonVice President of Operations
  • Ken RuppelVice President of Scientific & Medical Services
  • Ms. Lauren DeWitt ShellyExecutive VP of Legal, General Counsel & Group Company Secretary
  • Marianna SciortinoVice President of Sales
  • Ms. Sandra BlakeChief People Officer
  • Ms. Susanne MunkstedChief Precision Medicine Officer

Financials

Income Statement

Currency: GBP2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.40M4.59M7.37M10.37M13.44M12.70M13.94M19.50M23.70M32.16M38.44M
Growth (%)-+228.33%+60.63%+40.74%+29.59%-5.55%+9.82%+39.88%+21.51%+35.69%+19.53%
Cost of Revenue952.65K1.93M2.48M3.57M3.13M3.36M3.38M5.47M3.99M3.89M12.31M
Gross Profit444.92K2.66M4.89M6.80M10.31M9.33M10.57M14.04M19.71M28.27M26.12M
Gross Margin31.84%57.86%66.31%65.57%76.70%73.50%75.78%71.97%83.15%87.91%67.97%
Operating Expense508.31K1.77M3.99M5.59M8.19M9.94M10.02M13.46M22.72M30.73M25.86M
Operating Income-63.39K882.29K901.25K1.21M2.12M-610.00K550.00K575.00K-3.02M-2.46M266.00K
Operating Margin-4.54%19.23%12.23%11.69%15.78%-4.80%3.94%2.95%-12.73%-7.63%0.69%
EBITDA-59.84K584.17K922.18K1.30M847.58K178.00K2.35M3.61M2.36M2.77M6.08M
EBITDA Margin-4.28%12.73%12.51%12.50%6.31%1.40%16.85%18.50%9.95%8.62%15.81%
Net Income-103.49K747.14K663.19K632.31K398.00K263.00K561.00K724.00K-1.75M-1.70M97.00K
Net Income Margin-7.40%16.28%9.00%6.10%2.96%2.07%4.02%3.71%-7.37%-5.30%0.25%
R&D455.21K838.10K486.95K-78.00K------
R&D as % of Total Revenue32.57%18.26%6.61%-0.58%------
Interest Expense-87.98K110.74K301.58K222.40K51.00K88.00K122.00K66.00K54.00K58.00K
Interest Expense % of Total Revenue-1.92%1.50%2.91%1.65%0.40%0.63%0.63%0.28%0.17%0.15%

Balance Sheet

Currency: GBP2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.34M3.44M5.49M7.81M22.37M43.52M45.01M48.26M46.34M48.62M50.01M
Total Liabilities1.17M2.43M3.61M5.18M2.24M3.28M4.36M5.74M5.56M8.76M9.53M
Total Equity166.71K1.01M1.88M2.63M20.13M40.24M40.65M42.51M40.79M39.86M40.48M
Cash125.10K1.29M3.07M2.07M11.72M25.25M19.68M19.84M16.67M12.74M7.34M
Total Debt455.62K1.44M2.09M3.75M107.50K118.00K1.56M1.33M1.21M1.06M1.15M
Net Debt330.52K156.80K-982.08K1.67M-11.61M-25.14M-18.11M-18.51M-15.46M-11.68M-6.19M

Cash Flow

Currency: GBP2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-674.01K1.53M-954.04K-627.05K253.00K570.00K5.10M1.31M651.00K1.50M
Investing Cash Flow--29.00K-282.92K-1.11M-2.93M-6.29M-5.60M-4.87M-4.21M-4.03M-6.45M
Financing Cash Flow-184.82K527.45K1.05M13.29M19.61M-270.00K-132.00K-239.00K-64.00K-333.00K
Capital Expenditure029.03K282.92K1.11M2.93M6.29M5.60M4.87M4.86M4.63M71.00K
Free Cash Flow-644.98K1.25M-2.06M-3.55M-6.04M-5.03M278.00K-3.54M-3.98M1.43M
Dividends Paid-300.22K300.22K300.22K---191.00K---
FCF to OCF-95.69%81.56%216.10%566.76%-2387.75%-882.63%5.46%-270.33%-611.52%95.25%
Dividend Paid to FCF-46.55%23.99%-14.56%---68.71%---

Earnings

Report DateSep 9, 2019Apr 27, 2020Sep 7, 2020Mar 15, 2021Sep 15, 2021Mar 16, 2022Sep 28, 2022Mar 20, 2023May 21, 2025Sep 15, 2025Jan 15, 2026
EPS Estimate0.000.00-0.000.001.31-1.430.02-0.020.04
EPS Actual-0.030.030.02-0.010.000.01-0.010.020.01-0.030.03
Surprise------99.24%--98.60%-35.90%-22.41%-30.65%
Timing------After-hours--Pre-market-

Key Statistics & Ratios

Market Cap165.54M
Enterprise Value156.56M
Trailing P/E0.00
Forward P/E40.82
Price / Sales4.01
Price / Book4.20
EPS0.00
Book Value0.478
Revenue (TTM)41.33M
Gross Profit (TTM)34.25M
EBITDA3.86M
Profit Margin-0.66%
Operating Margin-23.01%
Return on Equity-0.71%
Return on Assets-1.03%
Shares Outstanding84.89M
Shares Float48.83M
Beta0.88
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%